Fairvalue-Calculator Fairvalue-Calculator
EN DE

Xenetic Biosciences, Inc (XBIO) Fair Value & Analysis

Healthcare · US · Market cap $6.6M

Price$2.90
Fair Value$3.09
Upside+6.6%
Quality95/100
Evidence: Low Range $2.04 – $3.86

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Xenetic Biosciences, Inc (XBIO) currently trades at $2.90, while our model-based Fair Value estimate is $3.09 — implying the stock looks roughly 6.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Xenetic Biosciences, Inc (XBIO) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.09 versus a price of $2.90 — about +7% (undervalued). Model-based estimate, not financial advice.
What is the fair value of XBIO?
Our 21-model fair value for Xenetic Biosciences, Inc is $3.09 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.90.
What is the quality score of XBIO?
Xenetic Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.